JAK2/FLT3-IN-1 TFA

• CAT Number: I045478
• CAS Number: 2928093-29-0
• Molecular Formula: C27H35F4N7O3
• Molecular Weight: 581.61
• Purity: ≥95%
• Synonyms: 2-[[1-[2-fluoro-4-[[5-methyl-4-(1-propan-2-ylpyrazol-4-yl)pyrimidin-2-yl]amino]phenyl]piperidin-4-yl]-methylamino]ethanol;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C25H34FN7O.C2HF3O2/c1-17(2)33-16-19(15-28-33)24-18(3)14-27-25(30-24)29-20-5-6-23(22(26)13-20)32-9-7-21(8-10-32)31(4)11-12-34;3-2(4,5)1(6)7/h5-6,13-17,21,34H,7-12H2,1-4H3,(H,27,29,30);(H,6,7)
• InChIKey: WIIIAEPAIQXSFK-UHFFFAOYSA-N
• SMILES: CC1=CN=C(N=C1C2=CN(N=C2)C(C)C)NC3=CC(=C(C=C3)N4CCC(CC4)N(C)CCO)F.C(=O)(C(F)(F)F)O

JAK2/FLT3-IN-1 TFA (Cat No.: I045478) is a potent dual inhibitor targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3), two key signaling proteins involved in hematologic malignancies. By blocking JAK2, it disrupts cytokine-mediated JAK/STAT signaling, while FLT3 inhibition suppresses growth of FLT3-mutated leukemic cells. The trifluoroacetic acid (TFA) salt form improves solubility and stability. JAK2/FLT3-IN-1 TFA is primarily used in acute myeloid leukemia (AML) and myeloproliferative neoplasm research, offering a valuable tool for developing targeted therapies against dual kinase-driven cancers.

Reference

[1]. Yang T, et al. Discovery of Potent and Orally Effective Dual JAK2/FLT3 Inhibitors for the Treatment of AcuteMyelogenous Leukemia and Myeloproliferative Neoplasms. J Med Chem. 2019 Oct 31.
[Content Brief]